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Poster Session-II 103Table 1. Results from a Prospective Geriatric Assessment
Before Allogeneic HCT for Recipients 50 years and over
Reference Interquartile
Predictor (Normal) Median Mean SD Range RangeComorbidity
CCI 0 0 0.49 0.73 0–3 0–1
KF 0 1 0.88 0.84 0–3 0–1
HCT-CI 0 3 2.8 2.00 0–9 1–4
CIRS-G 0 8 8.23 3.24 2–16 6–10Functional
ECOG PS 0 0 0.4 0.58 0–2 0–1
Frailty Index 0 2 1.79 1.25 0–5 1–3
SF36-PH 100 52 53 18.81 16–100 38–65Mental Health
SF36-MH 100 66 65 163.41 23–100 55–73Disability
ADL 12 12 11.89 0.41 9–12 12–12
IADL 14 14 13.15 1.76 4–14 13–14SD-Standard deviation282
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INHERITED
METABOLIC DISEASES: AN OVERVIEW OF LONG-TERM OUTCOMES IN A
SINGLE PEDIATRIC CENTRE
Gassas, A.1, Raiman, J.2, White, L.1, Finkelstein-Schechter, T.1,
Clarke, J.2, Doyle, J.1 1Hospital for Sick Children, Toronto, ON, Canada;
2Hospital for Sick Children
Over the past two decades, hematopoietic stem cell transplanta-
tion (HSCT) has been utilized as effective therapy for selected
inherited metabolic diseases (IMD’s). The primary objective of
HSCT for these disorders has been to promote long-term survival,
optimize quality of life and improve neuro-cognitive performance.
Between 1990–2007, in the Hospital for Sick Children in Toronto,
Canada, we performed 39 HSCT’s for IMD’s (10 related and 29
unrelated); 22 HSCT’s for 21 children with Hurler syndrome, 8
for malignant infantile osteopetrosis, 6 for X- linked adrenoleuko-
dystrophy (ALD), 2 for Gaucher’s syndrome, 1 for gangliosidosis,
1 for sialiosis type 1 and 1 HSCT for Neiman-Pick type 1A. Busulfan
(BU), cylophosphamide (CY) and single dose (300cGy) total body
irradiation (TBI) were used as a conditioning regimen in 33 patients
and 6 patients, in recent years of the study, received BU/CY and thy-
moglobulin. At a median follow up of 5.6 years (range 1.3–15.6 years)
18/21 patients with Hurler syndrome are alive. Educational status
was determined in 16 of them; 14 attended regular schools, some
with educational assistants, 1 attended a special needs school and 1
attended day-care. As of the last follow-up, 13/18 were ambulatory,
2 had some mobility difficulties and 1 was wheelchair-bound. For
non-Hurler’s, two children, 1 with osteopetrosis and 1 with ALD
suffered secondary graft failure and died from progressive disease.
The remaining children with osteopetrosis are alive and most chil-
dren attended regular school or education for the visually handi-
capped. One out of the five survivors with ALD has been
transferred to the adult follow up clinic and he is in full time employ-
ment. The patient with Neiman Pick type 1A progressed despite
durable engraftment.
Conclusion: These findings confirm that results and long-term
follow up of allogeneic HSCT in these serious and lethal IMD’s
are very encouraging and long term, independent and meaningful
survival, is possible.283
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGFA) GENE POLYMOR-
PHISMS MAY PREDICT THE RISK OF ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC TRANSPLANTATION: PREVENTIVE
EFFECT OF VEGF ON ACUTE GVHD
Kim, D.H.1, Lee, N.Y.2, Lee,M.-H.2, Sohn, S.K.2, Jang, J.H.1, Kim, K.1,
Jung, C.W.1 1Samsung Medical Center, Seoul, Korea; 2Kyungpook
National University Hospital, Daegu, Korea
Background: Microvessel injury is associated with the develop-
ment of graft-versus-host disease (GVHD), whereas high levels ofpost-transplant vascular endothelial growth factor (VEGF) have
a protective effect on severe acute GVHD (aGVHD) and trans-
plant-related mortality. The current study aimed to determine the
impact of VEGFA gene single nucleotide polymorphisms (SNPs)
on the risk of acute GVHD following allogeneic stem cell transplan-
tation (SCT).
Methods: Four VEGF gene SNPs were analyzed in 98 recipi-
ents using PCR/RFLP, i.e., –2578 C.A (rs699947), –460 T.C
(rs833061), 1405 G.C (rs2010963) and 1936 C.T
(rs3025039).
Results: Strong linkage disequilibrium was noted between loci
–2578, –460 and1405, but not between these and1936. Accordingly,
4 haplotypes were generated based on the genotypes of –2578, –460,
and 1405 as follows: CTC (47.9%), CTG (26.7%), ACG (24.2%),
and CCC (1.0%). The group with low producibility of VEGF (i.e.,
1936CT genotype and 2 copies of the ACG haplotype) showed
a higher incidence of acute GVHD: A significant association was
noted between the risk of grade 2–4 aGVHD and the 1 936 CT
(p 5 0.006), the –2578 AA (p 5 0.003), and the –460 CC
(p5 0.002) genotypes, and the ACG haplotype (p5 0.003). No asso-
ciation was observed between the VEGFA gene SNPs and chronic
GVHD.
Conclusion: The VEGFA gene SNPs might predict a lower risk
of acute GVHD. The current result suggests that VEGF might
play a protective role in the pathogenesis of acute GVHD.284
HIGHER INCIDENCE OF CMV REACTIVATION IN CMV SEROPOSITIVE
RECIPIENTS FOLLOWING FLUDARABINE BASED REDUCED INTENSITY
CONDITIONING TRANSPLANTS – A RETROSPECTIVE COMPARISON
WITH MYELOABLATIVE TRANSPLANTS
George, B.1, Gillroy, N.2, Kerridge, I.1, Gottlieb, D.1, Hertzberg, M.1,
Bradstock, K.1 1Westmead Hospital, Sydney, NSW, Australia; 2West-
mead Hospital, Sydney, NSW, Australia
Limited data exists on the incidence of Cytomegalovirus
(CMV) reactivation following fludarabine based reduced inten-
sity conditioning (RIC) transplants. A retrospective cohort study
was performed of high risk patients (CMV seropositive recipient
with either positive/negative donor) undergoing RIC or myeloa-
blative transplants (MAT), between January 2001 and June 2008,
to compare rates and risk factors for CMV reactivation. All sero-
positive recipients received pre-transplant ganciclovir followed
by valaciclovir as herpes virus prophylaxis. No post transplant
ganciclovir prophylaxis was given. Weekly monitoring for
CMV was done using qualitative PCR; if positive, quantification
was done using either pp65 antigenemia or quantitative PCR
(COBAS R). Eighty three RIC transplants (21 unrelated) and
127 MAT (48 unrelated) were performed during the study period.
The median age of RIC transplants (51 males; 32 females) was 49
years (range: 18–65) compared to 39 years (17–62) with MAT (72
males; 55 females). Anti-thymocyte globulin (ATG) or Alemtu-
zumab (Campath) was used for T cell depletion in 44 MAT
(34.6%) and 29 RIC transplants (34.9%) [p 5 1.000]. Acute graft
versus host disease (GVHD) was observed in 50.6% of RIC and
66.1% of MAT [p 5 0.030]. CMV reactivation was seen in 53
RIC transplants (63.8%) at a median of 47 days (range: 24 –
1977) and 61 MAT transplants (48% [p 5 0.030]) at a median
of 47 days (22 – 187) post transplant. Five reactivations each oc-
curred in the RIC (9.4%) and the MAT group (8.2%) beyond Day
100. CMV reactivation was higher with RIC transplants both in
the presence (73.8% vs 61.9%; p 5 0.230) and absence of
GVHD (53.6% vs 26.4%; p 5 0.003). Reactivation rates were
similar for unrelated donors (71.4% in RIC vs 62.5% in MAT;
p 5 0.586) but significantly higher in RIC with sibling donors
(61.2% vs 39.2% p 5 0.011). The use of ATG during condition-
ing did not influence reactivation. Of the 15 RIC transplants that
received Campath, 11 had CMV reactivation. The overall
incidence of CMV disease was 9.6% following RIC and 6.2%
following MAT (p 5 0.429). The higher incidence of CMV reac-
tivation and disease in RIC transplants highlights the need
for improved prophylactic and preemptive strategies,
potentially including the use of CMV specific CTL in this
vulnerable population.
